Navellier & Associates’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Navellier & Associates’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-25,916	Closed	-$2.07M	–	311
2022 Q2	$2.07M	Sell	25,916 -699	-3%	-$66.2K	0.44%	81
2022 Q1	$2.8M	Sell	26,615 -10,391	-28%	-$1.01M	0.48%	77
2021 Q4	$3.99M	Buy	37,006 +749	+2%	+$81.7K	0.58%	62
2021 Q3	$3.97M	Buy	36,257 +988	+3%	+$103K	0.6%	58
2021 Q2	$3.3M	Buy	35,269 +892	+3%	+$82.1K	0.5%	71
2021 Q1	$3.16M	Sell	34,377 -437	-1%	-$36.9K	0.57%	62
2020 Q4	$2.55M	Buy	34,814 +4,954	+17%	+$368K	0.46%	76
2020 Q3	$2.32M	Buy	+29,860	New	+$2.05M	0.51%	70
2015 Q4	–	Sell	-23,050	Closed	-$457K	–	328
2015 Q3	$457K	Buy	23,050 +10,550	+84%	+$333K	0.05%	171
2015 Q2	$434K	Buy	12,500 +500	+4%	+$15.3K	0.04%	227
2015 Q1	$312K	Hold	12,000	–	–	0.03%	275
2014 Q4	$155K	Buy	+12,000	New	+$150K	0.01%	318

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

Navellier & Associates's HZNP Position: Q3 2022 in Review

Navellier & Associates sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q3 2022, closing a stake of 25,916 shares — an estimated $2.07M sold.

Navellier & Associates first reported a position in HZNP in Q4 2014 and held it in 12 quarters. The position peaked at $3.99M in Q4 2021. 529 funds tracked by Wall St. Rank hold HZNP as of Q3 2022.

Navellier & Associates reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q3 2022 after selling out during the quarter.
Navellier & Associates sold 25,916 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q3 2022, an estimated $2.07M.
Navellier & Associates first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2014 and held it in 12 quarters.
Navellier & Associates's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $3.99M in Q4 2021.
529 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q3 2022.

Based on Navellier & Associates's 13F filing for Q3 2022, filed 9 Nov 2022.